Company news
Vera Therapeutics, Inc. (NASDAQ:VERA) news
Vera Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
October 2, 2026
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
October 1, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Vera Therapeutics Announces TRUTAKNA Stabilized eGFR and Prevented Kidney Disease Progression through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
September 16, 2026
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
September 15, 2026
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 10, 2026
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 9, 2026
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
July 7, 2026
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
June 10, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 2, 2026
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
May 4, 2026
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
March 24, 2026
Vera Therapeutics Appoints Christopher Hite to Board of Directors
March 4, 2026
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
February 26, 2026
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
January 28, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 9, 2026
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
January 7, 2026
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
December 8, 2025
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
December 7, 2025
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
November 25, 2025
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 23, 2025
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
November 9, 2025
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
November 6, 2025
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
November 5, 2025
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 4, 2025
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
October 21, 2025
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
October 16, 2025
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 5, 2025
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 9, 2025
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
June 2, 2025
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
June 1, 2025
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
May 5, 2025
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
April 2, 2025
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
February 26, 2025
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 25, 2025
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
January 12, 2025
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
November 17, 2024
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
November 10, 2024
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 6, 2024
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
October 25, 2024
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
October 1, 2024
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
October 1, 2024
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
September 15, 2024
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
September 11, 2024
Vera Therapeutics to Participate at September Investor Conferences
August 28, 2024